Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Gut and Liver
; : 452-456, 2012.
Article
in En
| WPRIM
| ID: wpr-58003
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS: This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori. METHODS: We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week. RESULTS: In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively. CONCLUSIONS: A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Rifamycins
/
Tetracycline
/
Bismuth
/
Ofloxacin
/
Helicobacter pylori
/
Helicobacter
/
Clarithromycin
/
2-Pyridinylmethylsulfinylbenzimidazoles
/
Amoxicillin
/
Metronidazole
Limits:
Humans
Language:
En
Journal:
Gut and Liver
Year:
2012
Type:
Article